The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis?

Clinical Hemorheology and Microcirculation

Volumn 36, Issue 4, 2007, Pages 277-289

  Leithäuser, Boris ^a,d   Fassbender, Monika ^b   Eickhoff, Monika ^b   Elg, Margareta ^c   Eichner, Gerrit ^b   Matthias, Fritz Reinhard ^b  

^a Clinic of Hoyerswerda   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Endotoxin; Leukocyte adhesion; Melagatran; Microcirculation; Permeability

Indexed keywords

ALBUMIN; ENDOTOXIN; FLUORESCEIN ISOTHIOCYANATE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MELAGATRAN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ENDOTHELIUM; ENDOTOXEMIA; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; IMAGE PROCESSING; IMMUNE RESPONSE; INFLAMMATORY DISEASE; LEUKOCYTE ADHERENCE; MALE; MESENTERY; MICROSCOPY; MICROVASCULATURE; NONHUMAN; PROTEIN FUNCTION; RAT; SEPSIS;

ANIMALS; ANTITHROMBIN III; AZETIDINES; BENZYLAMINES; CAPILLARY PERMEABILITY; CELL ADHESION; ENDOTHELIUM, VASCULAR; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTE ADHERENCE INHIBITION TEST; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; MESENTERY; MICROCIRCULATION; PEPTIDE HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR DISEASES;

EID: 34249909490     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. I.D. McGilvray and O.D. Rotstein, Role of the coagulation system in the local and systemic inflammatory response, World J. Surg. 22 (1998), 179-186.
2. C.T. Esmon, K. Fukudome, T. Mather et al., Inflammation, sepsis, and coagulation, Haematologica 84 (1999), 254-259.
3. M.V. De Wouwer, D. Collen and E.M. Conway, Thrombomodulin-protein C-EPCR system: Integrated to regulate coagulation and inflammation, Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1374-1383.
4. M. Levi, T. van der Poll and H.R. Buller, Bidirectional relation between inflammation and coagulation, Circulation 109 (2004), 2698-2704.
5. H.A. Lehr, F. Bittinger and C.J. Kirkpatrick, Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy? J. Pathol. 190 (2000), 373-386.
6. L. Harper and C.O. Savage, Pathogenesis of ANCA-associated systemic vasculitis, J. Pathol. 190 (2000), 349-359.
7. T. Sordia, J. Tatarishvili and G. Mchedlishvili, Hemorheological disorders in the microcirculation during septic shock in rats, Clin. Hemorheol. Microcirc. 35 (2006), 223-226.
8. M. Levi, T. van der Poll, H. ten Cate et al., The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia, Eur. J. Clin. Invest. 27 (1997), 3-9.
9. L. Ostrovsky, R.C. Woodman, D. Payne et al., Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion, Circulation 96 (1997), 2302-2310.
10. J.N. Hoffmann, B. Vollmar, D. Inthorn et al., Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway, Am. J. Physiol. 279 (2000), C98-C107.
11. R. Neviere, A. Tournoys, S. Mordon et al., Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats, Shock 15 (2001), 220-225.
12. B. Leithauser, J. Schumacher, S. Lendemans et al., Antithrombin attenuates microvascular leakage and leukocyte-endothelial interaction in response to endotoxin, Semin. Thromb. Hemost. 28 Suppl. 1 (2002), 87-94.
13. J.G.N. Garcia, F.M. Pavalko and C.E. Patterson, Vascular endothelial cell activation and permeability responses to thrombin, Blood Coag. Fibrinolysis 6 (1995), 609-626.
14. V.J. Toothil, J.A. van Mourik, H.K. Niewenhuis et al., Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells, J. Immunol. 145 (1990), 283-291.
15. D. Gustafsson and M. Elg, The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review, Thromb. Res. 109, Suppl. 1 (2003), S9-15.
16. M. Eriksson, A. Larsson, T. Saldeen et al., Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig, Thromb. Haemost. 80 (1998), 1022-1026.
17. M. Eriksson, S. Basu, A. Larsson et al., Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock, Expert. Opin. Investig. Drugs 9 (2000), 1129-1137.
18. T. Klyscz, M. Jünger, F. Jung et al., [Cap image - a new kind of computer-assisted video image analysis system for dynamic capillary microscopy], Biomed. Technik. 42 (1997), 168-175.
19. M. Larsson, U. Logren, M. Ahnoff et al., Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 766 (2002), 47-55.
20. J.C. Pinheiro and D.M. Bates, Mixed-Effects Models in S and S-PLUS, corr. 2nd printing, Springer-Verlag, New York Inc., 2001.
21. R.S. McCuskey, R. Urbaschek and B. Urbaschek, The microcirculation during endotoxemia, Cardiovasc. Res. 32 (1996), 752-763.
22. K. Ley, Molecular mechanisms of leukocyte rolling and adhesion to microvascular endothelium, Eur. Heart J. 14 (Suppl. I) (1993), 68-73.
23. M. Elg and D. Gustafsson, A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats, Thromb. Res. 117 (2006), 429-437.
24. K. Wahlander, M. Eriksson-Lepkowska, L. Frison et al., No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, Clin. Pharmacokinet. 42 (2003), 755-764.
25. S.I. Shedlofsky, B.C. Israel, C.J. McClain et al., Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism, J. Clin. Invest. 94 (1994), 2209-2214.
26. E.T. Morgan, Regulation of cytochromes P450 during inflammation and infection, Drug Metab. Rev. 29 (1997), 1129-1188.
27. E. Bredberg, T.B. Andersson, L. Frison et al., Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions, Clin. Pharmacokinet. 42 (2003), 765-777.
28. F.R. Jirik, T.J. Podor, T. Hirano et al., Bacterial lipopolysaccharide and inflammatory mediators augment Il-6 secretion by human endothelial cells, J. Immunol. 142 (1989), 144-147.
29. F.M. Szaba and S.T. Smiley, Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo, Blood 99 (2002), 1053-1059.
30. T. Tokunou, T. Ichiki, K. Takeda et al., Thrombin induces interleukin-6 expression through the cAMP response element in vascular smooth muscle cells, Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1759-1763.
31. P.C. Heinrich, J.V. Castell and T. Andus, Interleukin-6 and the acute phase response, Biochem. J. 265 (1990), 621-636.
32. K. Hirano and H. Kanaide, Role of protease-activated receptors in the vascular system, J. Atheroscler. Thromb. 10 (2003), 211-225.
33. C. Lehmann, V.H. Bac, D. Pavlovic et al., Metronidazole improves intestinal microcirculation in septic rats independently of bacterial burden, Clin. Hemorheol. Microcirc. 34 (2006), 427-438.
34. J.L. Vincent, Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology, Crit. Care 5 (2001), S1-S5.
35. C.J. Wiedermann and N.C. Kaneider, Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis, Ann. Med. 36 (2004), 194-203.
36. L. Caradonna, L. Amati, T. Magrone et al., Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance, J. Endotoxin. Res. 6 (2000), 205-214.
37. A.A. van Bodegraven, Haemostasis in inflammatory bowel diseases: clinical relevance, Scand. J. Gastroenterol. Suppl. (2003), 51-62.
38. S. Danese, C. de la Motte, A. Sturm et al., Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients, Gastroenterology 124 (2003), 1249-1264.
39. O.A. Hatoum, D.G. Binion, M.F. Otterson et al., Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation, Gastroenterology 125 (2003), 58-69.
40. F.S. Laroux and M.B. Grisham, Immunological basis of inflammatory bowel disease: role of the microcirculation, Microcirculation 8 (2001), 283-301.
41. T. Foitzik, M. Kruschewski, A. Kroesen et al., Does microcirculation play a role in the pathogenesis of inflammatory bowel diseases? Answers from intravital microscopic studies in animal models, Int. J. Colorectal. Dis. 14 (1999), 29-34.
42. S. Malhotra, D. Bhasin, N. Shafiq et al., Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond, Expert. Opin. Pharmacother. 5 (2004), 329-334.
43. S. Bloom, S. Kiilerich, M.R. Lassen et al., Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis, Aliment. Pharmacol. Ther. 19 (2004), 871-878.
44. J.N. Hoffmann, B. Vollmar, M.W. Laschke et al., Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms, Thromb. Haemost. 88 (2002), 242-252.